Why the study?
With recent FDA approval of 2 renal denervation systems, practical guidance was needed for interventional cardiologists to build a renal denervation program.
This review provides a practical roadmap for interventional cardiologists to establish a multidisciplinary renal denervation program for uncontrolled hypertension, addressing clinical workflows, operator training, and current United States reimbursement challenges.
Answers are grounded in this paper and cite their sources.
May support renal denervation program planning; leaves open prospective validation of outcomes and scalability.
Renal denervation (RDN) has emerged as a promising adjunctive therapy for hypertension, particularly in patients with poor blood pressure control despite pharmacologic and lifestyle interventions. With the recent approval of 2 RDN systems by the US Food and Drug Administration, there is growing opportunity for interested interventional cardiologists to develop expertise in this rapidly evolving, unsaturated field. This review serves as a comprehensive guide to building an RDN program, covering team development, training requirements, workflow design, and economic considerations. Interventional cardiologists, particularly fellows-in-training and those at early career stages, are uniquely positioned to advance this emerging technology by leveraging their multidisciplinary training, technological fluency, and openness to innovation to shape the future of interventional hypertension care. This blueprint offers a practical roadmap to capitalize on the clinical and career opportunities that RDN presents.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: